drugset / Trial / NCT00350636

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636 ↗

Phase 3 Completed 789 enrolled Watson Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-05

Outcome

Met primary endpoint

paper The mean number of urge incontinence episodes decreased significantly more in patients treated with oxybutynin chloride topical gel than in those given placebo (-3.0 vs -2.5 per day, p <0.0001). PMID 19233423 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 1 g Topical

Indications